NCT07334860

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)

A Two-Period, Open-label, Fixed-Sequence Study to Evaluate the Single-Dose Pharmacokinetics of Two Formulations of MK-1167 in Healthy Participants

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (estimated)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

Researchers are looking for new ways to treat Alzheimer's disease (AD). AD is a brain disease that causes a gradual decline in memory, thinking, and ability to carry out daily tasks. MK-1167 is a study medicine designed to treat symptoms of AD. Before giving a study medicine to people with a health condition, researchers first do studies in healthy people to find a safe dose of the study medicine. The goals of the trial are to learn: * What happens to different forms of MK-1167 in a healthy person's body over time * About the safety of MK-1167 and if people tolerate it

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	MK-1167	Oral administration

Timeline

• Start date: 2026-02-06
• Primary completion: 2026-05-28
• Completion: 2026-05-28
• First posted: 2026-01-12
• Last updated: 2026-03-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study